The overall slump in World economy caused by Brexit, US elections, threats of war involving countries from the far-east, coupled with the haphazard implementation of Demonetisation and lack of clarity about the procedures involved in implementation of GST has affected the Indian economy to the extent that companies have resorted to job cuts and shut down. This slump, however, is temporary, albeit a bit stretched. India’s Real GDP slowed down in the last quarter, but overall growth for the Current Fiscal is estimated to rebound to 7.00%, which is far better than that of the competing Developing and Developed countries. One of the major factors stalling the onset of rapid recovery is the lack of Private Investment due to reasons not limited to India alone. The constant disruptions of Parliament since 2012 for various reasons meant that GST was not implemented at a time when India could afford a temporary slowdown, but rather, at a time when the economy was showing signs of reco

The Indian Pharmaceutical Industry Accounts for 2.4% of the Global Pharmaceutical Industry by value, and 10% by volume. Further, India accounts for 20% of the global exports in the Pharmaceutical Industry, with a Total Business of USD 16.89 Billion, which is expected to reach USD 40.00 Billion by 2020. Boosted by lower cost R&D and Production, India is able to produce high quality medicines at lower prices. It is for this very reason that the Pharmaceutical Industry attracted 4% of the total FDIs in India. As per estimations, India is believed to see investments to the tune of USD 200 Billion on medical infrastructure in the next 10 years. With favourable policies of the Government in place and focus on “Pharma Vision 2020”, the Indian Pharmaceutical Industry is expected to reach USD 250.00 Billion by 2020. REASONS FOR INDIA’S EMERGENCE AS ONE OF THE WORLD LEADERS: India’s astronomical rise in this Industry can be attributed to the following: ·          Efficient prod